Five years after participating in an allogenic CAR-T cell therapy trial, a multiple myeloma patient has remained disease-free.
After being diagnosed with multiple myeloma in 2018, a 63-year-old patient underwent multiple years of standard-of-care therapy at Cleveland Clinic. Despite experiencing short-lived remission after numerous treatments, the disease continued to return, according to a Dec. 15 news release from the health system.
In November 2020, the patient was admitted to Cleveland Clinic Cancer Institute and received an infusion of allogenic CAR-T cells. While the patient experienced some side effects related to the severe immunosuppression, she did not develop cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.
In the five years since the infusion, she has received monthly intravenous immunoglobulin and oral antiviral medications to protect her immune system. The patient’s bloodwork and bone marrow biopsies have consistently confirmed she has achieved and maintained a complete response to therapy.
Leave a Reply